坦索罗辛联合他达拉非对比坦索罗辛单药治疗男性下尿路症状的双盲随机对照试验
这项双盲、平行组随机对照试验纳入140例>45岁、中度下尿路症状且Qmax 5-15 mL/s的男性,比较坦索罗辛单药(0.4 mg)与坦索罗辛联合他达拉非(5 mg)的疗效与安全性。联合组在IPSS、IPSS QoL、IIEF-5和Qmax改善上均显著优于单药组,PVR差异无统计学意义,无严重不良事件。
要点
- 联合组IPSS改善较单药组优1.69分(95%CI -1.4至-2.0)。
- 联合组IIEF-5改善较单药组优3.8分(95%CI 3.4-4.2)。
- 联合组Qmax改善较单药组优1.8 mL/s(95%CI 1.1-2.4)。
核心结论
- 坦索罗辛联合他达拉非在改善下尿路症状、生活质量、勃起功能和Qmax方面显著优于坦索罗辛单药,且未增加不良事件。
研究设计与样本
- 双盲、平行组随机对照试验,183例筛选,140例随机(A组71例,B组69例),116例(82.85%)完成研究。
- 纳入>45岁、中度LUTS且Qmax 5-15 mL/s的男性。
- A组接受坦索罗辛0.4 mg单药,B组接受他达拉非5 mg联合坦索罗辛;采用区组随机化和安慰剂设盲,意向性分析。
主要发现
- 联合组IPSS改善较单药组优-1.69(95%CI -1.4至-2.0)。
- 联合组IPSS QoL评分改善较单药组优-0.70(95%CI -0.60至-0.80)。
- 联合组IIEF-5评分改善较单药组优3.8(95%CI 3.4-4.2)。
- 联合组Qmax改善较单药组优1.8 mL/s(95%CI 1.1-2.4)。
- PVR差异无统计学意义;无严重不良事件,因不良事件脱落率2.85%,联合组最常见不良事件为肌痛(5例)。
临床怎么用
- 对于中度LUTS且Qmax 5-15 mL/s的>45岁男性,可考虑坦索罗辛联合他达拉非以同时改善排尿症状、生活质量和勃起功能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the efficacy and safety of tamsulosin vs the combination of tamsulosin and tadalafil in male lower urinary tract symptoms (LUTS). PATIENTS AND METHODS: This was a double-blinded, parallel-arm randomised controlled trial. Men aged >45 years with moderate LUTS and a maximum urinary flow rate (Qmax ) of 5-15 mL/s were included. One arm received 0.4 mg tamsulosin only (Group-A), while the second received 5 mg tadalafil with tamsulosin (Group-B). The primary outcome was the International Prostate Symptom Score (IPSS). Secondary outcomes were IPSS quality of life (QoL) score, five-item version of the International Index of Erectile Function (IIEF-5) score, Qmax , and post-void residual urine (PVR). Block randomisation was used. Placebo was used for blinding and allocation concealment. Intention-to-treat analysis was used for outcome measures. RESULTS: Of the 183 men screened, 140 were randomised (71 in Group-A, 69 in Group-B); 116 (82.85%) (61 in Group-A, 55 in Group-B) completed the study. Baseline characteristics were comparable. The improvements in the IPSS, IPSS QoL score, IIEF score and Qmax were -1.69 (95% confidence interval [CI] -1.4 to -2.0), -0.70 (95% CI -0.60 to -0.80), 3.8 (95% CI 3.4-4.2) and 1.8 mL/s (95% CI 1.1-2.4) respectively, in favour of the combination group. The difference in PVR was not significant. There were no serious adverse events (AEs). The dropout rate due to AEs was 2.85%. Myalgia (five patients) was the commonest AE in the combination group. CONCLUSION: The combination of tamsulosin and tadalafil produced significantly better improvements in LUTS, QoL, erectile function and Qmax compared to monotherapy with tamsulosin, without an increase in AEs.
引用
- Nagasubramanian S, John NT, Antonisamy B, et al. Tamsulosin and placebo vs tamsulosin and tadalafil in male lower urinary tract symptoms: a double-blinded, randomised controlled trial. BJU Int. 2020. PMID: 32012409. doi:10.1111/bju.15027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。